bioAffinity Technologies, Inc. - Common Stock (BIAF)
0.7113
-0.1787 (-20.08%)
NASDAQ · Last Trade: Apr 3rd, 3:47 PM EDT
Detailed Quote
Previous Close
0.8900
Open
0.7800
Bid
0.7111
Ask
0.7300
Day's Range
0.6706 - 0.8609
52 Week Range
0.2404 - 3.163
Volume
3,210,560
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
24,994,080
Chart
About bioAffinity Technologies, Inc. - Common Stock (BIAF)
bioAffinity Technologies, Inc. is a biotechnology company focused on developing innovative diagnostic and therapeutic solutions for the early detection and treatment of cancer. The company leverages its proprietary technologies to create advanced cellular and molecular products aimed at improving patient outcomes, particularly in areas where traditional methods fall short. By harnessing the power of biological mechanisms, bioAffinity seeks to provide healthcare professionals with novel tools for identifying cancer at its earliest stages and tailoring personalized treatment plans for patients. Read More
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
The regular session of the US market on Wednesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
U.S. stock futures were swinging between gains and losses on Tuesday after a mixed session on Monday. Futures of major benchmark indices were mixed in premarket trading. President Donald Trump‘s “Liberation Day”, the term he’s used for April 2nd, the day of incoming reciprocal tariffs, preceded a drop in stock prices.
After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today reported financial results for the year ended December 31, 2024.
ORLANDO, FLORIDA / ACCESS Newswire / March 28, 2025 / RedChip Companies will air interviews with bioAffinity Technologies, Inc. (Nasdaq:BIAF) and Can-Fite BioPharma Ltd. (NYSE American:CANF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, March 29, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) today released a case study in which a positive CyPath® Lung result led to the detection of a second primary lung cancer in a high-risk patient who was previously diagnosed with stage 1A non-small cell lung cancer and underwent successful surgery in 2023.
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) today released a study of a complex clinical case in which CyPath® Lung’s real-time assessment of the lung microenvironment identified a hidden recurrence of breast cancer in an 80-year-old high-risk patient.
